Moshirfar M, Thomson AC, West WB, et al. - Utilizing de-identified data from the medical records of 29 patients (48 eyes), researchers performed a non-randomized retrospective study to evaluate a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration results and published literature. SMILE was found to be an efficient and safe means of achieving spectacle independence and enhancing visual acuity in patients with myopic astigmatism. SMILE has the potential to improve clinical outcomes with improved nomogram guidance and advancements in technique. Surgeons must, however, be mindful of the potential for undercorrection in with-the-rule astigmatism and at higher preoperative cylinders and as well as the potential for overcorrection in against-the-rule and lower preoperative cylinder astigmatism.